NIO Inc. vs Roivant Sciences Ltd. Common Shares — how do they compare? NIO Inc. trades at $3.58 (market cap $8.62B), while Roivant Sciences Ltd. Common Shares trades at $35.44 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 2.9× NIO Inc.'s market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NIO Inc. for 81 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| NIO | ROIV | |
|---|---|---|
Market Cap | $8.62B | $24.72B |
Volume | 39,648,517 | 6,279,442 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.46 | $41.81 |
52-Week Low | $3.37 | $16.04 |
Typical Hold Time | 81 Days | 1 Days |
Enterprise Value | $6.52B | $20.99B |
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.41, down 3.67% today and near its 52-week low, reflecting bearish technical signals. The company reported Q3 2026 deliveries up 25.4% but continues to post net losses, with a -4.17% net income margin in 2026. Recent news highlights a strategic battery-swap partnership with Geely, valued at $2.38 billion for NIO Power, aiming to expand charging infrastructure amid a competitive EV price war in China.
The outlook remains challenging due to persistent losses and high debt, though revenue growth and analyst consensus suggest long-term potential. Risks include intense competition, margin pressure, and macroeconomic headwinds. With a $6.23 average price target, analysts see 83% upside, but investors must weigh profitability improvements against ongoing cash burn.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →